Viscocity Agent

Addition of pharmaceutical excipients is a commonly used approach to decrease the viscosity of highly concentrated protein formulations, which otherwise could not be subcutaneously injected or processed. The variety of protein–protein interactions, which are responsible for increased viscosities,…
Read More...

Thermogelling amphiphilic block copolymers have been widely investigated in the development of pharmaceutical drug carriers. In particular, thermosensitive gels based on poloxamer 407 (P407) have great potential for periodontal disease treatment, thanks to their ability to be liquid at room…
Read More...

RetaLac® by MEGGLE is a co-processed excipient comprising of equal parts of milled alpha-lactose monohydrate and hypromellose (USP substitution type 2208) with a nominal viscosity of 4000 cps. A specialized spray-agglomeration process generates textured, highly structured particles with d50 in…
Read More...

In recent years, the treatment of bacterial skin infections has been considered a major healthcare issue due to the growing emergence of antibiotic-resistant strains of Staphylococcus aureus. The incorporation of antibiotics in appropriate nanosystems could represent a promising strategy, able to…
Read More...

See an overview of the IOI Oleo specialties for Veterinary Applications. They are used for companion as well as for farm animals in following uses: • Injectables - SC and IM • Infusions - IV • Oral (e.g. paste, drench) • Pour-on / Spot-on formulations • Tick and flea collars …
Read More...

1| HARD FACTS ABOUT OUR HARD FATS The brand name WITEPSOL® is synonym for hard fats mainly used in  suppositories and ovules. Development and production of WITEPSOL® started back in the 1950s at the former Chemische Werke Witten, now known as IOI Oleo GmbH. Manufacturing takes place in a fully…
Read More...

Extended release tablets are commonly based on partially synthetic cellulose ethers, such as hypromellose (HPMC),  hydroxyethyl cellulose (HEC), or hydroxypropyl cellulose (HPC). Alginates offer an interesting, all-natural alternative to these polymers. The aim of the present study was to…
Read More...

During the development of a new drug, active materials are often available in small quantities for cost or process reasons. However, scientists have to understand their deformation behavior to design the best formulation possible and find suitable process parameters for production. Compaction…
Read More...

Purpose: When delivered via the subcutaneous route of application the volume of a drug is restricted to approx. 2 mL. For therapeutic proteins, such as mAbs or plasma proteins, this restriction requires the use of high protein concentrations. As can be seen by Figure 1 some proteins begin to become…
Read More...

Instability to storage and shipping conditions and injection administration remain major challenges in treating chronic conditions with biopharmaceuticals. Herein, formulations of poly(trehalose methacrylate) (pTrMA) are successfully optimized to stabilize insulin without appreciably increasing…
Read More...